Events & Presentations

SELLAS Life Science Phase 3 REGAL Study Update

Galinpepimut-S Update Call

SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

Shareholder Update Call - April 6, 2022

SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients RelapsedRefractory to Venetoclax in Ongoing Phase 1 Study

University of Pennsylvania Study Shows CD4 As Key Driver in Success of CAR-T Therapies to Cure Leukemia

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China